Suppliers and packagers for jadenu

jadenu

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910	NDA	Novartis Pharmaceuticals Corporation	0078-0654-15	30 TABLET, FILM COATED in 1 BOTTLE (0078-0654-15)	2015-03-30
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910	NDA	Novartis Pharmaceuticals Corporation	0078-0655-15	30 TABLET, FILM COATED in 1 BOTTLE (0078-0655-15)	2015-03-30
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910	NDA	Novartis Pharmaceuticals Corporation	0078-0656-15	30 TABLET, FILM COATED in 1 BOTTLE (0078-0656-15)	2015-03-30

Suppliers for JADENU (deferasirox) in the US and global supply chain: API, CDMO, and distributor landscape

Last updated: May 26, 2026

JADENU (deferasirox) is supplied in the US under the manufacturing and label-holder control of Novartis. The commercial supply chain for JADENU typically involves (1) deferasirox drug substance (API) supplied by qualified vendors, (2) drug product manufacturing performed by Novartis or its contract manufacturing partners, and (3) wholesale distribution through major US distributors listed in the FDA Drug Listing/wholesaler channels and on the downstream procurement side.

Who supplies the JADENU API (deferasirox) and which vendors manufacture deferasirox drug substance?

Featured snippet: JADENU uses deferasirox API. The specific API supplier names are governed by Novartis’ qualified supply chain and are typically disclosed through DMF/DMF letter access, inspection records, and limited public breadcrumbs rather than a single public “API suppliers” table.

What is the drug substance (API) for JADENU?

• Active ingredient: deferasirox
• Role in product: oral iron chelator used for chronic iron overload
• Manufacturing concept: API production and impurity control are handled under cGMP with grade-specific controls consistent with US requirements for oral chelators.

Where do API supplier names show up in practice?

Public identification of API vendors for a branded product usually comes from:

• FDA Drug Master File (DMF) references in filings (often not fully public without DMF access)
• Inspection observations and Establishment Registration links (indirect)
• Contract manufacturing databases used by procurement teams (subscription, not a single official public registry)
• Supply-chain disclosures in regulatory and compliance documentation (limited)

Which companies manufacture JADENU tablets and film-coated drug product (CDMO vs Novartis plants)?

Featured snippet: JADENU tablets are manufactured under cGMP by Novartis and/or qualified third-party manufacturers; plant-level names appear in FDA manufacturing site data and inspection history rather than a single public supplier list.

Drug product forms covered

• JADENU tablet (oral, deferasirox)

How to identify drug product manufacturers

Procurement and regulatory teams commonly map manufacturers using:

• FDA Establishment Registration and Listing (for manufacturing sites)
• Inspection history and site-specific NDA/BLA references
• Labeler and manufacturer fields in pharmacy supply systems

What are the main wholesale distributors for JADENU in the US?

Featured snippet: US supply of JADENU flows through large national wholesalers and specialty distributors that cover broad retail pharmacy and health-system channels.

Typical US distribution channels

• Large wholesalers servicing retail and chain pharmacies
• Specialty distribution arms for high-turnover or specialty spend categories
• GPO and hospital pharmacy procurement through contracted distribution lanes

How distributors impact availability

For iron chelators, continuity of supply depends on:

• Batch release timing
• Distribution lot allocation
• Forecasting accuracy across institutions and specialty pharmacies

What patent or exclusivity status affects supply and entry of alternatives to JADENU?

Featured snippet: JADENU is a branded deferasirox product; supply competition is shaped by generic and “authorized” competitive products and by any remaining regulatory exclusivity plus market approvals for alternatives.

Market implications

• If a generic or authorized alternative is approved and on formulary, purchasing shifts from branded supply to lower-cost equivalents.
• Patent estates and Orange Book-listed patents influence launch timing and exclusivity windows.

Paragraph IV and litigation-driven supply

Where litigation exists, it can drive:

• Settlement-based launch timing
• Supply diversion and inventory behavior
• Pharmacy substitution dynamics

How many JADENU suppliers exist globally, and what countries typically host production?

Featured snippet: Global manufacturing typically includes multiple cGMP sites across the major pharma manufacturing geographies; the exact count for JADENU depends on NDA manufacturing site registrations and labeler-specific approvals.

Common geography patterns for oral solid dose supply

• US EU and UK regulatory alignment sites
• Qualified manufacturing in major pharma supply hubs with established oral solid capabilities
• Backup sites for lifecycle management and supply continuity

What supply risks exist for JADENU and how do procurement teams mitigate them?

Featured snippet: For branded oral solid dose products, key risks are single-site reliance, batch release delays, and raw-material (API) continuity for specialty actives like deferasirox.

Risk factors specific to iron chelators

• Tight impurity specs and stability profiles for oral chelators
• Heat and moisture sensitivity in certain formulations
• Demand volatility from chronic patient populations and payer behavior

Mitigation actions

• Dual-source qualification for API and critical excipients where feasible
• Safety stock targets at the wholesaler and health-system levels
• Forecast alignment with launch and supply plans for lower-cost competitive products

JADENU vs deferasirox generics: how supplier changes after competitive entry?

Featured snippet: After generic availability, procurement shifts toward lower-cost suppliers and expands the number of qualifying SKUs through multiple generic manufacturers, while branded supplier count remains narrower.

Procurement shift mechanics

• Formulary inclusion of generics increases tender frequency and vendor count
• Pharmacy contract pricing favors generics with reliable fill
• Health-system continuity may keep branded inventory as a hedge in shortage periods

What to compare when evaluating supply

• Certificate of Analysis reliability and batch-to-batch consistency
• Cold-chain is generally not required for standard oral solid dose, but stability and packaging integrity still matter
• Lead times and minimum order quantities

Key Takeaways

• JADENU is supplied under Novartis control in the US, with deferasirox API and oral tablet drug product produced through qualified cGMP sites (Novartis and/or contracted manufacturers).
• API supplier names are not consistently published as a single public list; identification typically relies on DMF-linked filings, inspection and registration mapping, and supply-chain qualification data used by procurement teams.
• US distribution runs through major wholesalers and specialty channels, and availability is driven by batch release and lot allocation more than by the number of “suppliers” in a generic sense.
• Competitive entry via generics changes the commercial supplier set by expanding the number of approved SKUs and procurement choices, while branded supply usually stays concentrated.

FAQs

1. How do I find the FDA manufacturing site for JADENU tablets?
2. What is the fastest way to identify deferasirox API suppliers for qualification?
3. Do JADENU shortages typically stem from API or tablet manufacturing constraints?
4. Which wholesalers commonly distribute JADENU to US retail pharmacies?
5. How does generic entry of deferasirox affect JADENU purchasing and inventory strategy?

References

1. FDA. “Drug Establishment Registration and Drug Listing.” FDA Databases.
2. FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” FDA.
3. FDA. “Drug Master Files (DMF).” FDA Guidance and Database Descriptions.